Compare Enveric Biosciences Inc (ENVB) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Shell PLC — how do they compare? Enveric Biosciences Inc trades at $1.42 (market cap $5.32M), while Shell PLC trades at $85 (market cap $228.96B). The key difference: Shell PLC is far larger — about 43037.6× Enveric Biosciences Inc's market cap, and Shell PLC pays a 3.69% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SHEL | |
|---|---|---|
Market Cap | $5.32M | $228.96B |
Sector | Health | Energy |
52-Week High | $17.40 | $94.15 |
52-Week Low | $1.28 | $70.28 |
Enterprise Value | $408.82K | $281.49B |
Dividend Yield | — | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Shell (SHEL) trades at $85.43, up 1.21% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong valuation metrics with a P/E of 13.18 and P/S of 0.93, supported by recent earnings beats and a 7.01% net income margin. Recent news highlights strategic moves including the ARC Resources acquisition and Venezuela gas field development, while cash flow trends indicate operational strength despite net outflows.
Outlook remains positive with a consensus price target of $122.20, reflecting 43% upside potential, driven by robust gas trading and refining margins. Key risks include Middle East production disruptions and volatile oil prices, but analyst sentiment is strongly bullish with 69% buy ratings. The dividend yield and debt reduction efforts provide additional shareholder value support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
